Representative Experience

• Advised Curevo Vaccine, a clinical-stage biotechnology company dedicated to developing varicella-zoster virus (VZV) vaccines with improved tolerability, on its acquisition by Eli Lilly and Company valued at up to US$1.5bn.*
• Advised Vaccine Company, a privately held preclinical-stage biotechnology company developing next-generation vaccines for infectious diseases, on its acquisition by Eli Lilly and Company valued at up to US$1.55bn.*
• Advised Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B), shingles vaccine candidate, and differentiated clinical-stage pipeline, on its acquisition by Sanofi for US$2.2bn.*
• Advised Cidara Therapeutics, a publicly traded biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, on its acquisition by Merck, with a total transaction value of approximately US$9.2bn.*
• Advised Kate Therapeutics, a privately held company focused on developing gene therapies for inherited neuromuscular diseases, on its acquisition by Novartis for US$1.1bn in a combination of upfront cash and potential milestone payments.*
• Advised Kate Therapeutics on its exclusive license of its preclinical gene therapy candidate for treatment of X-linked myotubular myopathy to Astellas Pharma/Astellas Gene Therapies.*
• Advised Editas Medicine, a publicly traded gene editing company focused on developing transformative medicines for serious diseases, on its license agreement with Vertex Pharmaceuticals for a nonexclusive license of Editas Medicine’s Cas9 gene-editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including CASGEVY™ (exagamglogene autotemcel), with an upfront payment to Editas Medicine of US$100m, plus annual licensing fees ranging from US$10m to US$40m per year through patent expiry in 2034.*
• Advised Neomorph, a privately held company developing molecular glue degraders, on its multi-target collaboration and license agreement with Novo Nordisk to develop and commercialize molecular glue degraders, with a total deal value of up to US$1.46bn, plus tiered royalties.*
• Advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s US$364.2m upsized initial public offering.*
• Advised Chimerix, a biopharmaceutical company focused on developing medicines for patients facing deadly diseases, on its acquisition by Jazz Pharmaceuticals for $8.55 per share in cash, for a total transaction value of approximately US$935m.*
• Advised Chimerix on its acquisition of Oncoceutics, Inc., a clinical-stage biotechnology company developing small molecule imipridones, including ONC201 (dordaviprone) and ONC206, with upfront merger consideration to Oncoceutics shareholders of US$78m in Chimerix stock and cash, development, regulatory, and sales milestone payments of up to US$360m, and royalties on combined sales of ONC201 and ONC206 of 15% of the first US$750m in annual net sales and 20% of annual net sales over US$750m.*
• Advised Chimerix on its sale to Emergent BioSolutions Inc. of TEMBEXA® (brincidofovir), an FDA-approved medical countermeasure for smallpox, with an upfront fee of US$225m, US$112.5m in milestone payments, 20% royalty on U.S. gross profit on volumes above 1.7 million treatment courses, and 15% royalty on ex-U.S. gross profit.*
• Advised Cidara Therapeutics on its concurrent US$240m private placement financing and definitive agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388, an investigational, long-acting drug-Fc conjugate (DFC) developed to prevent seasonal and pandemic influenza.*
• Advised Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention of seasonal influenza, for an upfront payment of US$27m and an aggregate of US$753m in R&D funding and development, regulatory, and commercial milestones, plus tiered royalties on worldwide sales.*
• Advised argenx BV, a global immunology innovation company, on its global collaboration and exclusive license agreement with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, for argenx’s proprietary clinical-stage anti-CD70 therapeutic antibody cusatuzumab, with an upfront payment to argenx of US$300m, up to €1.3 billion in development, regulatory, and sales milestones, and tiered double-digit royalties, together with a US$200m equity investment in argenx by Johnson & Johnson Innovation – JJDC, Inc.*
• Advised argenx BV on the creation and financing of OncoVerity, Inc., an asset-centric spin-off and 50/50 joint venture by argenx and University of Colorado Anschutz Medical Campus/University of Colorado Health, focused on optimizing and advancing the development of cusatuzumab in acute myeloid leukemia (AML) and the exclusive license to OncoVerity for global development and commercialization rights to cusatuzumab.*
• Advised Amazentis SA on its global collaboration and license agreement with Nestlé Health Science to develop and commercialize dietary supplements, selected foods and beverages, and medical nutrition products using Amazentis’ patented Urolithin A technology.*
• Advised Ionis Pharmaceuticals, a leader in antisense drug discovery and development, on a global collaboration, option, and license agreement with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the GI tract. Pursuant to the agreement, Ionis was to receive a US$35m upfront payment covering three distinct GI programs, including a payment to initiate human lead optimization on the first collaboration target. Ionis was also eligible to receive nearly US$800m in development, regulatory, and sales milestone payments and license fees for the programs.*

*Matters handled prior to joining Foley.